Change of concentration of biochemical markers of dysfunction of endothelium at intake of inhibitors of tyrosinekinase of I and II generations at patients with a chronic myeloid leukemia as risk factor of development of cardiovascular complications

CML), the accepting inhibitors tyrosine of kinases (TKI) I and II generations (TKI1 TKI2 respectively), development arterial hypertension. Material methods . Examination 137 patients with CML in chronic phase (CP) is conducted, median age — 47 years. 24 them were for first time verified diagnosis earlier did not accept TKI, they have made group control. Other accepted TKI: 39 imatinib 400 mg/day, 36 dasatinib 100 38 nilotinib 800 mg/day) more than 6 months. In biochemical analysis blood indicators lipidic range defined. Level detection ET-1 VEGF was by means enzyme immunoassay. To all measurement heart rate (HR) pressure (ABP) on both hands at an interval 2 minutes from previous once taken. Results authentically significant increase levels systolic diastolic ABP (?<0,001) comparison control, noted. The most serious changes are noted nilotinib. groups statistically level C-reactive protein, fibrinogen, homocysteine, endothelin-1 control revealed. expressed found nilotinib, values parameters changed significantly differ revealed reception dazatinib. Conclusion As a result conducted research endothelium variation function TKI1 above-stated can be used as additional diagnostic criteria assessment risk hypertension TKI.